Acta Oncologica · 2020 · 62 citations · 27 references
MedicineOncologyPathologyCancer ImmunologyGynecologic OncologyTumor ImmunologyImmuno-oncology BiomarkersNatural Killer Cell BiologyNatural Killer Cell FunctionOvarian CancerTumor GradingTumor-infiltrating LymphocytesCd8 Positive T CellsCd8+ Tumor-infiltrating LymphocytesHigh-grade Serous Ovarian CarcinomaNatural Killer Cell BiomarkersNatural Killer Cell-mediated Tumor ControlOvarian Cancer Prognostic BiomarkersOvarian Tumor GradingPrognostic Variables
Introduction: The aim of the present study was to investigate the prognostic impact of intratumoral cytotoxic T cells, Natural Killer (NK) cells, neutrophils and PD-L1 expression in patients with epithelial ovarian cancer.Methods: All patients diagnosed with high-grade serous carcinoma (HGSC) in Denmark in 2005 were included in the study. Immunohistochemical staining for PD-L1, CD8, CD66b and CD57 was performed on tumor tissue from 283 patients. Cell densities were analyzed using a digital image analysis method. The primary endpoint was overall survival (OS).Results: The median OS for HGSC patients was 30 months. It was 45 months in patients with high level of CD57+ NK cells (≥10 cells/mm2) compared with 29 month in patients with low level (<10 cells/mm2) (p = .0310). The median OS was 37 and 25 months in patients with high vs. low level of CD8+ T cells (cutoff 80 cells/mm2) (p = .0008). In multivariate analysis, high numbers of CD57+ NK cells and CD8+ T cells remained independent markers of favorable OS, adjusted hazard ratio (HR) 0.67; p = .041, and HR 0.72; p = .020, respectively. PD-L1 expression was associated with improved OS (37 months vs. 22 months, p = .0006), but was only borderline significant in the multivariate analysis (HR 0.77, p = .061). CD66b + neutrophils had no association with OS.Conclusions: In patients with HGSC tumor-infiltrating CD57+ NK cells and CD8+ T cells had favorable prognostic impact, while PD-L1 expression had borderline favorable prognostic significance. CD66b + neutrophils had no prognostic association. These findings may influence future immunotherapy development.
27
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · New England Journal of Medicine · 2016 · 10.1K citations · Full text
Medicine, Oncology, Pharmacology +17
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Lin Zhang, José R. Conejo-García, Dionyssios Katsaros et al. · New England Journal of Medicine · 2003 · 3.4K citations · Full text
Medicine, Immunology, Oncology +17
Eiichi Sato, Sara H. Olson, Jiyoung Ahn et al. · Proceedings of the National Academy of Sciences · 2005 · 2.4K citations · Full text
Life Sciences, Immunology, Oncology +17
Junzo Hamanishi, Masaki Mandai, Masashi Iwasaki et al. · Proceedings of the National Academy of Sciences · 2007 · 1.4K citations · Full text
Medicine, Immunology, Oncology +17